Natco Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Natco Pharma from all sources in a single place.

Natco Pharma Ltd.

26 Aug 2026, 02:46PM

857.60

-0.67%

SAST

Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni

pdf

Natco Pharma Ltd.

25 Aug 2026

857.60

-0.67%

Natco Pharma to invest $14 mn in US-based biotechnology firm eGenesis Inc

Business Standard

Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added. In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock. The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said. The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..

Number of FII/FPI investors increased from 285 to 298 in Jun 2026 qtr.

Natco Pharma to invest $14 million in eGenesis Inc

Business Line | 25 Aug 2026

Natco Pharma Ltd.

25 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.

pdf

Natco Pharma Ltd.

24 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Investor Meet

pdf

Natco Pharma Ltd.

21 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit

pdf

Natco Pharma Ltd.

19 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Investor Meet

pdf

Natco Pharma Ltd.

19 Aug 2026

857.60

-0.67%

Investor Presentation

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor Presentation

pdf

Natco Pharma Ltd.

18 Aug 2026

857.60

-0.67%

Earnings Call

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026

pdf

Natco Pharma Ltd.

16 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited

pdf

Natco Pharma Ltd.

16 Aug 2026

857.60

-0.67%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.

pdf

Is Natco Pharma Ltd. worth buying?

619 Votes:

Buy 82.39%

Sell 7.59%

Hold 10.02%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf